Olema Pharmaceuticals, Inc. 2025-2026 Proxy Voting Records

Description as filed by funds: Election of the four nominees for Class III director named in the accompanying proxy statement to hold office until the Company's 2029 Annual Meeting of Stockholders and until their successors have been duly elected and qualified: Sean Bohen, M.D., Ph.D.

Olema Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Sean Bohen, M.D., Ph.D.”): 67,474,365 for, 1,165,382 withheld, per its Form 8-K filed June 23, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1—Election of Directors Final Voting Results The Company's stockholders elected each of the four nominees as Class III directors to hold office until the Company's 2029 annual meeting of stockholders and until their respective successors have been duly elected and qualified.”
Support: 98% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 60 asset managers below reported 24,395,814 for, 380,132 withheld, 17,295 abstained.

Showing the 25 largest of 60 asset managers. See all 60 in the interactive database.

Description as filed by funds: Election of the four nominees for Class III director named in the accompanying proxy statement to hold office until the Company's 2029 Annual Meeting of Stockholders and until their successors have been duly elected and qualified: Scott Garland

Olema Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Scott Garland”): 66,184,382 for, 2,455,365 withheld, per its Form 8-K filed June 23, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1—Election of Directors Final Voting Results The Company's stockholders elected each of the four nominees as Class III directors to hold office until the Company's 2029 annual meeting of stockholders and until their respective successors have been duly elected and qualified.”
Support: 96% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 60 asset managers below reported 24,131,081 for, 644,861 withheld, 17,299 abstained.

Showing the 25 largest of 60 asset managers. See all 60 in the interactive database.

Description as filed by funds: Election of the four nominees for Class III director named in the accompanying proxy statement to hold office until the Company's 2029 Annual Meeting of Stockholders and until their successors have been duly elected and qualified: Yi Larson

Olema Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Yi Larson”): 50,371,668 for, 18,268,079 withheld, per its Form 8-K filed June 23, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1—Election of Directors Final Voting Results The Company's stockholders elected each of the four nominees as Class III directors to hold office until the Company's 2029 annual meeting of stockholders and until their respective successors have been duly elected and qualified.”
Support: 73% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 60 asset managers below reported 20,488,431 for, 4,245,528 withheld, 59,282 abstained.

Showing the 25 largest of 60 asset managers. See all 60 in the interactive database.

Description as filed by funds: Election of the four nominees for Class III director named in the accompanying proxy statement to hold office until the Company's 2029 Annual Meeting of Stockholders and until their successors have been duly elected and qualified: Andrew Rappaport

Olema Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Andrew Rappaport”): 67,276,575 for, 1,363,172 withheld, per its Form 8-K filed June 23, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1—Election of Directors Final Voting Results The Company's stockholders elected each of the four nominees as Class III directors to hold office until the Company's 2029 annual meeting of stockholders and until their respective successors have been duly elected and qualified.”
Support: 98% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 60 asset managers below reported 24,358,353 for, 417,593 withheld, 17,295 abstained.

Showing the 25 largest of 60 asset managers. See all 60 in the interactive database.

Description as filed by funds: Approval, on an advisory basis, of the compensation of the Company's named executive officers.

Olema Pharmaceuticals, Inc.’s own tally for this item (“2. Advisory Vote on Executive Compensation Final Voting Results”): 67,969,902 for, 653,979 against — passed, per its Form 8-K filed June 23, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The Company's stockholders approved, on an advisory basis, the compensation awarded to the Company's named executive officers, as disclosed in the Proxy Statement.”
Support: 99.0% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Also reported under other wordings, matched to the same row of Olema Pharmaceuticals, Inc.’s official tally and shown with their own fund figures; their managers are not in the figures or the table on this card: “14A Executive Compensation” (4 managers, 2,666,277 for).

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 61 managers: 24,793,254 for, 84,625 against. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 171 managers: 60,990,690 for, 1,036,077 against, 12 abstained, 94 not voted. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: Ratification of the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2026.

Olema Pharmaceuticals, Inc.’s own tally for this item (“3. Ratification of Selection of Independent Registered Public Accounting Firm Final Voting Results”): 75,811,449 for, 271,918 against — passed, per its Form 8-K filed June 23, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 3: Ratification of Selection of Independent Registered Public Accounting Firm Final Voting Results”
Support: 99.6% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 61 asset managers below reported 24,877,879 for.

Showing the 25 largest of 61 asset managers. See all 61 in the interactive database.